FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 577 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer MOST POPULAR New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... January 26, 2021 Cancer clinical trials – learning lessons from the COVID-19 pandemic May 19, 2021 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping November 17, 2020 Load more HOT NEWS Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer Reunión anual de la American Society of Clinical Oncology de 2023:... Bus Driver Wears Different Costume Each Day To Make Kids Smile... How TRACERx is helping us predict lung cancer’s next move
